The role of PARP inhibitors in gastrointestinal cancers

Area of Science:

• Oncology
• Genetics
• Pharmacology

Background:

• Biomarker-driven targeted therapy is established for breast and gynecological cancers using BRCA mutations for DNA damage response (DDR) drug sensitivity.
• Poly (ADP-ribose) polymerases (PARP) inhibitors show efficacy in homologous recombination (HR) pathway deficiencies.
• Gastrointestinal (GI) cancers currently lack personalized treatment strategies based on DDR alterations.

Purpose of the Study:

• To review the current use of PARP inhibitors in GI cancers.
• To explore homologous recombination deficiency (HRD) as a predictive biomarker for PARP inhibitor sensitivity in GI cancers.
• To address the clinical need for personalized treatment in GI cancers.

Main Methods:

• Literature review of PARP inhibitor use in pancreatic, gastroesophageal, hepatobiliary, and colorectal cancers.
• Exploration of homologous recombination deficiency (HRD) as a biomarker.
• Analysis of current methods for determining HR status in different tumor types.

Main Results:

• The application of DDR targeted therapies, including PARP inhibitors, is expanding beyond breast and gynecological cancers.
• There is a lack of uniformity in determining HR status across different GI tumor types.
• Current PARP inhibitor sensitivity prediction in GI cancers relies on analogies from other cancer types.

Conclusions:

• There is an urgent need to understand the implications of DDR alterations for treating GI cancers.
• HRD status requires standardized determination methods for effective biomarker use in GI cancers.
• Further research is needed to personalize PARP inhibitor therapy for GI cancer patients.